---
title: 'Director, Strategic Engagements (Northeast) at Xenon Pharmaceuticals'
canonical: 'https://feeny.ai/job/director-strategic-engagements-northeast-xenon-pharmaceuticals-united-states-8t8qs9hefn4y'
type: 'job'
last_seen: '2026-10-29'
---

# Director, Strategic Engagements (Northeast) at Xenon Pharmaceuticals

- **Company:** Xenon Pharmaceuticals
- **Location:** United States
- **Employment:** full-time
- **Work type:** remote
- **Posted:** 2026-10-21
- **Last confirmed live:** 2026-10-29
- **Apply:** https://jobs.ashbyhq.com/xenon/a2abf9a4-e9ff-486f-bdd3-8a8f2575a0ea

## Job description

Who We Are: Xenon Pharmaceuticals ([NASDAQ:XENE](https://www.nasdaq.com/market-activity/stocks/xene)) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. We are looking for great people who thrive in a respectful, collaborative, inclusive, and productive culture to join the Xenon team. What We Do: We are advancing an [exciting product pipeline](https://xenon-pharma.com/pipeline) to address indications with high unmet medical need, including epilepsy, depression and pain. Our Phase 3 azetukalner program represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. In March 2026, we announced positive topline data from our Phase 3 X-TOLE2 study of azetukalner in focal onset seizures (FOS), and we submitted a New Drug Application to the Food and Drug Administration in the third quarter of 2026. Our Phase 3 epilepsy program also includes a second FOS study, X-TOLE3, which would support regulatory submissions outside the U.S., and the X-ACKT study in primary generalized tonic-clonic seizures, which would support regulatory submissions for an additional epilepsy indication. We also have multiple Phase 3 azetukalner clinical trials underway in major depressive disorder (MDD) and bipolar depression (BPD), based on topline data from our Phase 2 X-NOVA clinical trial. In addition, we are proud of our strong heritage in human genetics, deep understanding of ion channel biology, and expertise in novel chemistries to enable potent, selective ion channel targeting. We continue to advance an early-stage pipeline of novel therapeutic candidates, including Phase 1 studies for XEN1701 and XEN1720 (targeting Nav1.7) and XEN1120 (targeting Kv7), which are being developed for pain. Backed by a strong balance sheet to support our growth plans, we continue to build a fully integrated, premier neuroscience company with strong discovery, clinical development, corporate, and commercial operations. About the Role: We are seeking a Director, Strategic Engagements, Northeast, to join our team. The individual will be an integral member of the Commercial team and will support commercially focused HCP engagement activities for Azetukalner.

Key primary responsibility is to support key US Commercial Strategic market development strategies for the epilepsy launch. Individuals should be an exceptional business leader with deep epilepsy experience who will work Regionally to maintain: 1) KOL Engagement and 2) Uncover key market impact drivers 3) Support regional business planning across matrix colleagues. This role will ensure close working relationships with cross-functional partners in a compliant manner.

This position requires close collaboration with the Commercial team, Medical Affairs and other key business partners to elevate corporate brand awareness/ advocacy. This role requires demonstrated ability to thrive in a dynamic and ambiguous environment. Position will require greater than 50% travel (can be up to 75% travel) to field-based educational events (many occurring on weekends). This includes internal meetings, advisory boards, medical meetings, and congresses.

This position reports to the Senior Director, Customer Engagement, and will be fully remote.

## RESPONSIBILITIES:

- Identify, cultivate, and maintain long-term relationships with national and regional epilepsy KOLs, advisors, and other influential stakeholders.
- Own commercial KOL influence mapping, including stakeholder profiling, engagement strategies, and communication plans that inform customer prioritization and commercial planning.
- Monitor and synthesize stakeholder insights, treatment trends, unmet needs, and competitive dynamics, translating findings into actionable recommendations that inform commercial strategy, launch readiness, and regional business decisions.
- Serve as a strategic advisor to Commercial leadership by providing market intelligence, stakeholder perspectives, and recommendations that shape launch planning, customer engagement strategies, and business priorities.
- Support launch readiness initiatives by identifying and engaging key stakeholders who influence awareness, perception, advocacy, treatment positioning, and early adoption of Azetukalner within assigned regions.
- Lead cross-functional coordination across Commercial, Medical Affairs, Market Access, Advocacy, and other matrix partners to ensure aligned customer engagement strategies and execution.
- Drive coordinated account planning by integrating stakeholder insights and partnering across matrix teams to develop and execute aligned engagement plans for priority customers and accounts.
- Identify emerging market opportunities, barriers to adoption, and customer needs, and recommend actions that strengthen launch preparedness and commercial execution.
- Attend and lead strategic engagement activities at national and regional congresses, professional meetings, and key industry events, including stakeholder mapping, partner engagement, and field education support.
- Collaborate with Marketing, Analytics, Medical Affairs, and other cross-functional partners to refine disease-state education, brand strategy, customer engagement approaches, and market development initiatives.
- Identify and develop strategic partnerships with professional societies, advocacy organizations, and other external stakeholders to advance disease awareness, education, and advocacy efforts.
- Facilitate and coordinate high-impact engagements between Xenon senior leadership and national and regional KOLs.
- Formalize meetings (live, virtual, Congress) with senior leadership and National and Regional KOLs
- Develop and propose short- and long-term objectives for the function in accordance with overall Company strategies and plans
- Plan and manage budget proposals and approved budgets in accordance with the Company’s strategic and operating plans and Finance policies
- Recruit, lead, direct, develop, coach and evaluate direct reports, if any, in accordance with the Company’s Human Resource policies and practices
- Act in accordance with Company policies, including, for example, the Code of Business Conduct and Ethics and ensure policies are understood and followed by direct reports, if any
- Travel is 50-75%
- Region covers: MA, NY, PA, NJ, CT, RI, VT, NH, ME
- International travel may be required
- Other duties as assigned

## QUALIFICATIONS:

- A minimum of a BA/BS Degree in a related field is required; MBA, PharmD, PhD or other related graduate degree preferred
- A minimum of 10 years of experience in Epilepsy marketing, medical, key account management, sales, or sales leadership, ideally engaging with KOLs/Influential HCPs and professional healthcare organizations
- Deep understanding and experience working cross functionally with various key internal & external stakeholders with a strong ability to innovate, collaborate and deliver results with desired outcomes
- Demonstrated understanding of key industry trends and ability to develop strategies to stay ahead of the competition and maximize patient outcomes
- Demonstrated ability to build and manage relevant and lasting customer relationships with strong focus on patient impact and outstanding customer centricity
- Excellent interpersonal, verbal and written communication skills
- Able to work independently under tight timelines and be willing to contribute significantly to day-to-day operations as needed Our Total Rewards program includes base salary, target bonus, and stock options, as well as a full range of benefits including medical, dental, vision, short-& long-term disability, accidental death & dismemberment, and life insurance programs, Employee Assistance Program, travel insurance, and retirement savings programs with company matching contributions. Xenon encourages time to rest and re-charge through vacation, personal days, sick days, and an end-of-year company shutdown. Xenon highly values employee development and has an expanding Training, Learning & Development program, including a Tuition Assistance program for advanced degrees.

## About Xenon Pharmaceuticals

## Company Overview
- **One-liner**: Xenon Pharmaceuticals is a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and commercializing life-changing therapeutics for people living with neurological and psychiatric disorders.
- **Entity Type**: Public (Ticker: XENE on Nasdaq)
- **Headquarters**: Burnaby, British Columbia, Canada
- **Founded**: 1996
- **Founders**: Not publicly listed as individual founders; the company was founded based on a platform science capable of discovering new genetic targets to treat human disease.

## Core Business
- **Primary industry/industries**: Biotechnology, Neuroscience, Pharmaceuticals
- **Target customers**: Patients with neurological and psychiatric disorders (epilepsy, major depressive disorder, bipolar depression, pain); healthcare providers; payers.
- **Mission or purpose statement**: "To deliver innovative medicines that provide a brighter future for people living with neurological and psychiatric disorders." [xenon-pharma.com](https://xenon-pharma.com/about)

## Products & Services
Xenon’s pipeline is focused on ion channel science, specifically potassium (KV7) and sodium (NaV) channel modulators.

- **Azetukalner (KV7 Potassium Channel Opener)**: The lead late-stage investigational candidate. It is in multiple Phase 3 clinical trials for:
    - Focal onset seizures (Phase 3 X-TOLE2 completed, X-TOLE3 ongoing)
    - Primary generalized tonic-clonic seizures (Phase 3 X-ACKT)
    - Major depressive disorder (Phase 3 X-NOVA2 and X-NOVA3)
    - Bipolar depression (Phase 3 X-CEED)
- **XEN1120 (KV7 Potassium Channel Opener)**: An early-stage (Phase 1) candidate for the treatment of pain.
- **XEN1701 (NaV1.7 Sodium Channel Inhibitor)**: An early-stage (Phase 1) candidate for the treatment of pain.
- **NBI-921355 (Partnered with Neurocrine Biosciences)**: A NaV1.2/1.6 inhibitor in development for epilepsy, pain, and psychiatry. [xenon-pharma.com](https://xenon-pharma.com/pipeline)

## Market Standing
- **Valuation/Market Cap**: Not publicly available in the provided search results. As a public company, this fluctuates daily.
- **Key Metric**: Annual Revenue of $7.5M (as per LinkedIn). As a clinical-stage biotech, the primary focus is on pipeline progress and cash runway rather than revenue.
- **Notable Investors/Partners**: Neurocrine Biosciences (partner for NBI-921355). The company has also had strategic partnerships with multiple premier biopharmaceutical companies focused on pain, metabolic, and cardiovascular disease. [xenon-pharma.com](https://xenon-pharma.com/about)
- **Growth Signals**: The company is in a significant growth phase, having initiated multiple Phase 3 clinical trials for its lead candidate, azetukalner, across epilepsy, major depressive disorder, and bipolar depression. This represents a major expansion of its clinical pipeline and a transition towards a late-stage, fully integrated biopharmaceutical company. [xenon-pharma.com](https://xenon-pharma.com/about)

## Competitive Advantages
- **Deep Expertise in Ion Channel Biology**: Xenon is one of the scientific leaders in ion channel drug discovery, with a specific focus on potassium (KV7) and sodium (NaV) channel modulators. This is a highly specialized and technically difficult area of drug development. [xenon-pharma.com](https://xenon-pharma.com/about)
- **Proprietary Pipeline**: The company has a wholly-owned, late-stage pipeline led by azetukalner, a novel KV7 potassium channel opener being studied across multiple high-need indications (epilepsy, MDD, bipolar depression). This provides significant potential upside and control over its future.
- **Strong Scientific Foundation**: Founded on a platform capable of discovering new genetic targets, the company has a deep history of translating genetic insights into novel therapeutic candidates. [xenon-pharma.com](https://xenon-pharma.com/about)
- **Strategic Partnerships**: A history of partnerships with premier biopharmaceutical companies (e.g., Neurocrine Biosciences) validates its platform and provides non-dilutive funding. [xenon-pharma.com](https://xenon-pharma.com/about)

## Strategic Focus
- **Advancing Late-Stage Pipeline**: The primary focus is on executing the Phase 3 clinical programs for azetukalner across epilepsy, major depressive disorder, and bipolar depression, with the goal of regulatory approval and commercialization.
- **Expanding Early-Stage Pipeline**: Continuing to advance early-stage candidates (XEN1120, XEN1701) for pain and other high-need indications.
- **Building a Fully Integrated Company**: Transitioning from a discovery and development company to one with commercial capabilities, as evidenced by the hiring of a Chief Commercial Officer. [xenon-pharma.com](https://xenon-pharma.com/about)
- **Deepening Ion Channel Leadership**: Maintaining its position as a scientific leader in ion channel drug discovery, with a deep focus on potassium (KV7) and sodium (NaV) channel modulators. [xenon-pharma.com](https://xenon-pharma.com/about)

## Why Work Here
- **Mission-Driven Work**: Employees are united by a clear and compelling mission to deliver innovative medicines for patients with neurological and psychiatric disorders who have been underserved for too long. [xenon-pharma.com](https://xenon-pharma.com/about)
- **Culture of Collaboration and Impact**: The company describes itself as collaborative, ambitious, resilient, ethical, and science-driven. The culture is shaped by the "XenonCARES" program, which focuses on professional growth, wellness, and community. [xenon-pharma.com](https://xenon-pharma.com/join-us)
- **Competitive Compensation & Benefits**: Offers a total compensation package including base salary, performance-based bonuses, and equity. Benefits include comprehensive medical, dental, and vision coverage (US and Canada), a retirement savings program with a generous employer match, and a tuition reimbursement program. [xenon-pharma.com](https://xenon-pharma.com/join-us)
- **Work Flexibility**: The company values flexibility and provides a stipend for work-from-home setups. They also offer generous paid vacation time and an annual holiday shutdown. [xenon-pharma.com](https://xenon-pharma.com/join-us)
- **Growth & Development**: Recognizes and supports team member growth through leadership and development opportunities, a tuition reimbursement program, and recognition programs for both big and small wins. [xenon-pharma.com](https://xenon-pharma.com/join-us)
- **Work Model**: Hybrid/Remote-friendly with a stipend for home office setups. Offices are located in Burnaby, British Columbia (HQ) and the United States. [xenon-pharma.com](https://xenon-pharma.com/join-us)
- **Diversity & Inclusion**: The company states it cultivates and celebrates diversity, viewing diverse backgrounds, experiences, and opinions as a great asset, and is committed to fostering a safe and inclusive environment. [xenon-pharma.com](https://xenon-pharma.com/join-us)

## Sources
1. [xenon-pharma.com](https://xenon-pharma.com/)
2. [xenon-pharma.com](https://xenon-pharma.com/about)
3. [xenon-pharma.com](https://xenon-pharma.com/join-us)
4. [xenon-pharma.com](https://xenon-pharma.com/pipeline)
5. [linkedin.com](https://www.linkedin.com/company/xenonpharma)

## Other roles at Xenon Pharmaceuticals

- [Manager/Senior Manager, Quality Assurance, GCP](https://feeny.ai/job/manager-senior-manager-quality-assurance-gcp-xenon-pharmaceuticals-boston-brx3p0gvjntd) — Boston, MA
- [Senior Director, Regulatory Affairs, CMC](https://feeny.ai/job/senior-director-regulatory-affairs-cmc-xenon-pharmaceuticals-boston-81ef8453d6fy) — Boston, MA
- [Senior Manager/Associate Director, CMC, Analytical Development](https://feeny.ai/job/senior-manager-associate-director-cmc-analytical-development-xenon-f9c9m6tc7htf) — Boston, MA
- [Director, Strategic Engagements (Central)](https://feeny.ai/job/director-strategic-engagements-central-xenon-pharmaceuticals-united-states-02fkkc8at4vp) — United States
- [Associate Director, Patient Marketing](https://feeny.ai/job/associate-director-patient-marketing-xenon-pharmaceuticals-boston-qgbkezstxc3m) — Boston, MA
- [Research Associate 1 or 2, Biology (12 Month Contract)](https://feeny.ai/job/research-associate-1-or-2-biology-12-month-contract-xenon-pharmaceuticals-exc5ys7rt69b) — Vancouver, Canada
- [Director/Senior Director, Development Program Management, CMC](https://feeny.ai/job/director-senior-director-development-program-management-cmc-xenon-89ek6c47bep8) — Boston, MA
- [National Account Director](https://feeny.ai/job/national-account-director-xenon-pharmaceuticals-united-states-x5sqr7e2hgk9) — United States
- [Vice President, Clinical Development (Pain)](https://feeny.ai/job/vice-president-clinical-development-pain-xenon-pharmaceuticals-boston-87z5xs8a2kn6) — Boston, MA
- [Associate Director, CMC, Drug Substance](https://feeny.ai/job/associate-director-cmc-drug-substance-xenon-pharmaceuticals-boston-2gn1ar8j2cqt) — Boston, MA